Indications
Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
Composition
- Active substance
- temoporfin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Foscan
- Active substance
- temoporfin
- ATC code
- L01XD05
- Therapeutic area
- Head and Neck Neoplasms, Carcinoma, Squamous Cell
- Marketing authorisation holder
- Biolitec Pharma Ltd
- Status
- Authorised